X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES UNICHEM LAB VENUS REMEDIES/
UNICHEM LAB
 
P/E (TTM) x -4.2 -63.5 - View Chart
P/BV x 0.2 0.7 21.9% View Chart
Dividend Yield % 0.0 2.4 -  

Financials

 VENUS REMEDIES   UNICHEM LAB
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
UNICHEM LAB
Mar-18
VENUS REMEDIES/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs126382 33.0%   
Low Rs61234 26.1%   
Sales per share (Unadj.) Rs301.8116.3 259.5%  
Earnings per share (Unadj.) Rs-24.9-18.9 131.4%  
Cash flow per share (Unadj.) Rs2.5-11.7 -21.7%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %01.6 0.0%  
Book value per share (Unadj.) Rs293.3381.0 77.0%  
Shares outstanding (eoy) m12.3470.34 17.5%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.32.6 11.7%   
Avg P/E ratio x-3.8-16.3 23.1%  
P/CF ratio (eoy) x36.7-26.2 -140.0%  
Price / Book Value ratio x0.30.8 39.4%  
Dividend payout %0-26.4 0.0%   
Avg Mkt Cap Rs m1,15421,668 5.3%   
No. of employees `0000.92.3 40.6%   
Total wages/salary Rs m3932,006 19.6%   
Avg. sales/employee Rs Th4,026.13,587.8 112.2%   
Avg. wages/employee Rs Th425.0880.0 48.3%   
Avg. net profit/employee Rs Th-331.8-583.7 56.8%   
INCOME DATA
Net Sales Rs m3,7248,180 45.5%  
Other income Rs m23610 3.7%   
Total revenues Rs m3,7478,790 42.6%   
Gross profit Rs m395-1,320 -29.9%  
Depreciation Rs m338505 67.0%   
Interest Rs m35480 442.3%   
Profit before tax Rs m-275-1,295 21.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3233 94.6%   
Profit after tax Rs m-307-1,331 23.1%  
Gross profit margin %10.6-16.1 -65.7%  
Effective tax rate %-11.5-2.6 444.9%   
Net profit margin %-8.2-16.3 50.7%  
BALANCE SHEET DATA
Current assets Rs m2,63823,318 11.3%   
Current liabilities Rs m2,3054,635 49.7%   
Net working cap to sales %8.9228.4 3.9%  
Current ratio x1.15.0 22.8%  
Inventory Days Days135122 111.2%  
Debtors Days Days46121 38.1%  
Net fixed assets Rs m4,8718,163 59.7%   
Share capital Rs m123141 87.7%   
"Free" reserves Rs m3,49626,660 13.1%   
Net worth Rs m3,61926,801 13.5%   
Long term debt Rs m1,3743 41,648.5%   
Total assets Rs m7,50931,890 23.5%  
Interest coverage x0.2-15.2 -1.5%   
Debt to equity ratio x0.40 308,422.7%  
Sales to assets ratio x0.50.3 193.4%   
Return on assets %0.6-3.9 -16.1%  
Return on equity %-8.5-5.0 170.8%  
Return on capital %1.6-4.5 -34.8%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m04,356 0.0%   
Fx outflow Rs m5170-   
Net fx Rs m-5174,356 -11.9%   
CASH FLOW
From Operations Rs m514-1,123 -45.8%  
From Investments Rs m-12316,487 -0.7%  
From Financial Activity Rs m-387-8,811 4.4%  
Net Cashflow Rs m46,552 0.1%  

Share Holding

Indian Promoters % 32.9 50.1 65.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 15.1 1.2%  
FIIs % 0.6 3.0 19.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 31.7 209.5%  
Shareholders   20,121 20,176 99.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Flat; Pharma Stocks Gain(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.5% while the Hang Seng is up 1%.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 26, 2018 10:57 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS